Proteon Therapeutics Inc. (PRTO) and ChromaDex Corporation (NASDAQ:CDXC) Comparison side by side

This is a contrast between Proteon Therapeutics Inc. (NASDAQ:PRTO) and ChromaDex Corporation (NASDAQ:CDXC) based on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Proteon Therapeutics Inc. N/A 0.00 21.02M -1.19 0.00
ChromaDex Corporation 30.02M 6.45 33.92M -0.63 0.00

In table 1 we can see Proteon Therapeutics Inc. and ChromaDex Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics Inc. 0.00% -293.7% -61%
ChromaDex Corporation -112.99% -77.8% -61.9%

Risk and Volatility

Proteon Therapeutics Inc.’s volatility measures that it’s 54.00% more volatile than Standard & Poor’s 500 due to its 1.54 beta. ChromaDex Corporation’s 1.26 beta is the reason why it is 26.00% more volatile than Standard & Poor’s 500.

Liquidity

Proteon Therapeutics Inc. has a Current Ratio of 10.7 and a Quick Ratio of 10.7. Competitively, ChromaDex Corporation’s Current Ratio is 3.2 and has 2.7 Quick Ratio. Proteon Therapeutics Inc.’s better ability to pay short and long-term obligations than ChromaDex Corporation.

Analyst Recommendations

Recommendations and Ratings for Proteon Therapeutics Inc. and ChromaDex Corporation can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Proteon Therapeutics Inc. 0 0 1 3.00
ChromaDex Corporation 0 0 0 0.00

Institutional and Insider Ownership

The shares of both Proteon Therapeutics Inc. and ChromaDex Corporation are owned by institutional investors at 70.3% and 17.7% respectively. Proteon Therapeutics Inc.’s share owned by insiders are 1%. Comparatively, ChromaDex Corporation has 2.3% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Proteon Therapeutics Inc. 6.02% 6.33% -21.78% -30.98% -4.86% -7.37%
ChromaDex Corporation -19.72% -22.97% -25.59% -25.39% -54.4% -51.53%

For the past year Proteon Therapeutics Inc. has stronger performance than ChromaDex Corporation

Summary

On 6 of the 10 factors Proteon Therapeutics Inc. beats ChromaDex Corporation.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.